(Q24247998)

29 July 2017

7 August 2017

1 reference

title

Dornase alfa for cystic fibrosis (English)

0 references

Deoxyribonuclease for cystic fibrosis (English)

1 reference

29 July 2017

Recombinant human deoxyribonuclease for cystic fibrosis (English)

1 reference

7 August 2017

0 references

Ashley P Jones

1

0 references

Colin Wallis

2

0 references

Catherine E Kearney

3

0 references

C E Kearney

1

1 reference

29 July 2017

C E Wallis

2

2 references

29 July 2017

7 August 2017

A P Jones

1

1 reference

7 August 2017

publication date

21 July 2003

0 references

1 January 2000

1 reference

29 July 2017

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

7 August 2017

published in

2 references

29 July 2017

7 August 2017

issue

2

1 reference

29 July 2017

3

1 reference

7 August 2017

page(s)

CD001127

2 references

29 July 2017

Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Dornase Aerosol Effect on Sputum Viscosity in Cases Of Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Nebulised hypertonic saline for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Dornase alfa in early cystic fibrosis lung disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Dornase alpha and exhaled NO in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

RhDNase before airway clearance therapy improves airway patency in children with CF.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

[Clinical development of rhDNase in the United States]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

[Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Efficacy of Human Recombinant DNase in Pediatric Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

DNase in stable cystic fibrosis infants: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Composite Spirometric–Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Recombinant DNase in cystic fibrosis: a protocol for targeted introduction through n-of-1 trials. Scottish Cystic Fibrosis Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001127

7 January 2021

10.1002/14651858.CD001127

Identifiers

DOI

2 references

29 July 2017

7 August 2017

1 reference

29 July 2017

1 reference